Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sven de Vos

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Nature Clinical Practice. Nephrology|January 26, 2007
Acute lymphoblastic leukemia presenting as acute renal failureWilliam M Suh, Zev A Wainberg, Sven de Vos, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution ExperienceSanaz Ghafouri, Kathleen Fenerty, Gary Schiller, et al.
International Journal of Oncology|March 11, 2004
Imprinting status of DLK1 gene in brain tumors and lymphomasDong Yin, Dong Xie, Sven De Vos, et al.
Lancet (London, England)|February 21, 2002
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression studyWolf K Hofmann, Sven de Vos, David Elashoff, et al.
Stem Cells (Dayton, Ohio)|June 16, 2005
Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiationMartina Komor, Saskia Güller, Claudia D Baldus, et al.
Experimental Hematology|July 13, 2010
Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndromeSaskia Gueller, Martina Komor, Daniel Nowak, et al.
Leukemia & Lymphoma|February 7, 2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trialsMelhem Solh, Richard I Fisher, André Goy, et al.
Leukemia Research|May 4, 2004
Allelic loss during progression of follicular lymphomaSeisho Takeuchi, Sven de Vos, Naoko Takeuchi, et al.
Leukemia & Lymphoma|November 25, 2020
Safety and efficacy of navitoclax, a BCL-2 and BCL-X<sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a studySven de Vos, John P Leonard, Jonathan W Friedberg, et al.
Blood|October 16, 2012
Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell deathMary C Clark, Mabel Pang, Daniel K Hsu, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Nature Clinical Practice. Nephrology|January 26, 2007
Acute lymphoblastic leukemia presenting as acute renal failureWilliam M Suh, Zev A Wainberg, Sven de Vos, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2021
Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution ExperienceSanaz Ghafouri, Kathleen Fenerty, Gary Schiller, et al.
International Journal of Oncology|March 11, 2004
Imprinting status of DLK1 gene in brain tumors and lymphomasDong Yin, Dong Xie, Sven De Vos, et al.
Lancet (London, England)|February 21, 2002
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression studyWolf K Hofmann, Sven de Vos, David Elashoff, et al.
Stem Cells (Dayton, Ohio)|June 16, 2005
Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiationMartina Komor, Saskia Güller, Claudia D Baldus, et al.
Experimental Hematology|July 13, 2010
Identification of defects in the transcriptional program during lineage-specific in vitro differentiation of CD34(+) cells selected from patients with both low- and high-risk myelodysplastic syndromeSaskia Gueller, Martina Komor, Daniel Nowak, et al.
Leukemia & Lymphoma|February 7, 2013
Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trialsMelhem Solh, Richard I Fisher, André Goy, et al.
Leukemia Research|May 4, 2004
Allelic loss during progression of follicular lymphomaSeisho Takeuchi, Sven de Vos, Naoko Takeuchi, et al.
Leukemia & Lymphoma|November 25, 2020
Safety and efficacy of navitoclax, a BCL-2 and BCL-X<sub>L</sub> inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a studySven de Vos, John P Leonard, Jonathan W Friedberg, et al.
Blood|October 16, 2012
Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell deathMary C Clark, Mabel Pang, Daniel K Hsu, et al.
Pageof 7